trending Market Intelligence /marketintelligence/en/news-insights/trending/0hjcm4vjprxwoncprlvtcg2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In this list

Aralez launches allergy drug in Canada

Brazil Pay TV Down Record Amount In 2019, With Losses Continuing In Q1'20

Case Study: Transforming Sales Enablement Data at a Global Advertising and Media Firm

Impact of COVID 19 on US Video Entertainment Trends

Key Credit Risk Factors When Assessing Banks In The Context Of COVID-19

Aralez launches allergy drug in Canada

Aralez Pharmaceuticals Inc. announced the commercial launch of Blexten in Canada for the treatment of seasonal allergic rhinitis and chronic spontaneous urticaria.

The drug will be distributed by Tribute Pharmaceuticals Canada Inc., an Aralez subsidiary, and will have eight years of market exclusivity.

According to Aralez, the Canadian antihistamine market is currently valued at approximately C$120 million per year.

Chronic spontaneous urticaria is a disabling skin condition that causes red, swollen, itchy and painful hives. Allergic rhinitis occurs when the immune system overreacts to particles in the air.